Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYN6G0)

Drug Name
TGP-580 Drug Info
Synonyms CS-23; HbFGF, Takeda
Indication
Disease Entry ICD 11 Status REF
Neurodegenerative disorder 8A20-8A23 Discontinued in Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMYN6G0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Fibroblast growth factor-2 (FGF2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sucralfate DMP9HBO Acne vulgaris ED80 Approved [3]
Squalamine DM3PS2E Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
DVC1-0101 DMUGBQK Arteriosclerosis BD40 Phase 2 [5]
Bemarituzumab DMWNYIE Gastric adenocarcinoma 2B72 Phase 2 [6]
FPA144 DM1EBRK Bladder cancer 2C94 Phase 1 [7]
RG-8803 DMI0CYV Diabetic retinopathy 9B71.0 Terminated [8]
2-Sulfhydryl-Ethanol DMJBO3D Discovery agent N.A. Investigative [9]
N,O6-Disulfo-Glucosamine DMYCV7U Discovery agent N.A. Investigative [9]
BIBF100 DMUWO6D Multiple myeloma 2A83 Investigative [10]
1,4-Dideoxy-O2-Sulfo-Glucuronic Acid DM9KUQZ Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-2 (FGF2) TTGKIED FGF2_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001922)
2 Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
3 Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
4 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
5 DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.